Yazar "Akcin, Soner" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor
    (Taylor & Francis Ltd, 2009) Okuyucu, Esra E.; Guven, Oguz; Duman, Taskin; Gorur, Sadik; Melek, Ismet M.; Akcin, Soner; Yilmazer, Serkan
    Objective: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. Method: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). Results: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. Conclusion: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors. [Neurol Res 2009; 31: 313-315]
  • Küçük Resim
    Öğe
    Urodynamic evaluation of acute effects of sildenafil on voiding among males with erectile dysfunction and symptomatic benign prostate
    (Tubitak Scientific & Technological Research Council Turkey, 2012) Yalcinkaya, Fatih Rustu; Davarci, Mursel; Akcin, Soner; Gokce, Ahmet; Guven, Esref Oguz; Inci, Mehmet; Balbay, Mevlana Derya
    Aim: To evaluate the acute effects of sildenafil citrate on micturition of men with erectile dysfunction and symptomatic benign prostatic hyperplasia using urodynamic parameters. Materials and methods: Between June and December 2009, a total of 50 patients over the age of 40 participated in the study. The patients were admitted to our hospital with erectile dysfunction and moderate to severe lower urinary symptoms with benign prostatic hyperplasia. To examine the sexual function of the participants, we used the IIEF-5 Sexual Health Inventory for Men questionnaire. Patients were randomly divided into 2 groups: a treatment group and a control group. A basal urodynamic evaluation was performed in both groups. After the urodynamic evaluation, 50 mg of sildenafil was given to the patients in the control group and 1 h later a second evaluation was performed. Following the urodynamic evaluation, a placebo was given to the patients in the control group and then a second evaluation was performed after 1 h. Results: A statistically significant increase was seen in maximal flow and average flow (Qmax and Qave) after 1 h in the treatment group. The increase in the control group was not significant. Conclusion: Based on the study findings, we suggest that sildenafil has an effect on micturition in the short term. However, to determine the role of sildenafil in the treatment of BPH/LUTS, further studies with larger patient groups are needed.